Patent Law

Ranbaxy to settle with Takeda over Actos (pioglitazone)?

By Lawrence B. Ebert, Esq.

The Indian drug major [Ranbaxy] , which last week announced a high-profile patent settlement deal with Pfizer on Lipitor, the world's largest selling drug, may now review its litigation with Japan's Takeda on Actos (pioglitazone).

The blockbuster medicine for diabetes clocked annual sales of over $1 billion in the US alone. Ranbaxy is known to be the first one to have challenged the patent of Actos and expects a six-month marketing exclusivity in the US.

If the report is correct, it would appear that there is a major patent litigation strategy shift at Ranbaxy.

See also

Pfizer, Ranbaxy settle Lipitor matter

Full post as published by IPBiz on June 22, 2008 (boomark / email).